PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
Tumour Biol
; 36(8): 5753-5, 2015 Aug.
Article
em En
| MEDLINE
| ID: mdl-26234767
ABSTRACT
Protein phosphatase 2A (PP2A) is a well-known tumor suppressor frequently inhibited in human cancer. Alterations affecting PP2A subunits together with the deregulation of endogenous PP2A inhibitors such as CIP2A and SET have been described as contributing mechanisms to inactivate PP2A in prostate cancer. Moreover, recent findings highlight that functional inactivation of PP2A could represent a key event in the acquisition of castration-resistant phenotype and a novel molecular target with high impact at both clinical and therapeutic levels in prostate cancer.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Autoantígenos
/
Fatores de Transcrição
/
Proteína Fosfatase 2
/
Chaperonas de Histonas
/
Neoplasias de Próstata Resistentes à Castração
/
Proteínas de Membrana
Limite:
Humans
/
Male
Idioma:
En
Revista:
Tumour Biol
Ano de publicação:
2015
Tipo de documento:
Article